Avalo Therapeutics Inc (NAS:AVTX)
$ 9.55 -0.44 (-4.4%) Market Cap: 99.93 Mil Enterprise Value: 18.62 Mil PE Ratio: 0 PB Ratio: 4.39 GF Score: 47/100

Cerecor Inc Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients - Corporate Call Transcript

Jul 26, 2021 / 08:30PM GMT
Release Date Price: $8006.4 (-2.46%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Cerecor Initial Phase 1B Result for CERC-002 in Moderate to Severe Crohn's Disease Patients Conference Call.

At this time, all participants are in a listen-only mode. (Operator Instructions).

I would now like to turn the conference over to your speaker host today, Mr. Schond Greenway. Please go ahead.

Schond Greenway
Cerecor Inc. - Chief Financial Officer

Thank you, [Olivia]. Good day, everyone and thank you for joining us today to discuss the initial results from our Phase 1b proof of concept study evaluating CERC-002 at investigational first-in-class fully human anti-LIGHT monoclonal antibody in adult patients with moderate to severe Crohn's disease.

Speaking on the call today, we have Mike Cola, our Chief Executive Officer; Dr. Gary Neil, our Chief Scientific Officer; Dr. Jeffrey Wilkins, our Chief Medical Officer; and Dr. Gerald Dryden, Study Investigator and Professor of Medicine and Director of the Inflammatory Bowel Disease Program at the University of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot